Crystalys Therapeutics
Focus: Crystalys Therapeutics is a Series A biotech company focused on developing oral URAT1 inhibitors for gout, a metabolic disease affecting millions globally. Based in San Diego, the company is early-stage with a focused therapeutic approach.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Open Jobs
0
About Crystalys Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Crystalys Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Post-LOE
Generic post-loss-of-exclusivity product with no strategic focus for this gout-focused biotech.
Help build intelligence for Crystalys Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.